A combination of gold and green tea compounds could provide a potential treatment for prostate cancer, a new study has claimed.

Researchers from the University of Missouri found that a combination of a compound found in green tea leaves and radioactive gold nanoparticles were able to destroy the tumour cells.

The tea compound, which was attracted to the cancerous cells, helped to deliver the gold nanoparticles were able to destroy the tumour cells.

The new study conducted on Mouse is published in the Proceedings of the National Academy of Sciences.

Researchers said large doses of chemotherapy, which sometimes have toxic side effects, are currently used to treat a variety of cancers, but the new treatment would require doses that are “thousands of times” lower than that of chemotherapy.

The particles are small enough to destroy the diseased cells, but leave the healthy surrounding tissue and cells intact.

“By combining a natural component in green tea that has an affinity for prostate tumour cells, we have formed gold nanoparticles that have a high uptake in tumour cells,” ABC News quoted, Mr Dr Cathy Cutler, research professor at the MU Research Reactor as saying.

“This formulation of gold nanoparticles, which has shown such tumour cell death at such a low dose in a model of aggressive human prostate cancer indicates it could be effective for aggressive prostate cancer,” Cutler who’s also the co author of the study said.

The green tea compound used in the study, known as epigallocatechin—gallate, or EGCg, is an antioxidant that has been shown in prior research to have cancer fighting properties.

Dr David Crawford, professor of surgery and radiation oncology at the University of Colorado Health Sciences Center, said the use of nanoparticles for a number of areas in medicine to deliver therapy is “exciting,” and, while early in development, still promising.

But Dr Derek Raghavan, president of Levine Cancer Institute at Carolinas HealthCare System, called the study, “headline hunting” and noted the gap between data and clinical application is vast.

(This article was published on July 25, 2012)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.